November 18th, 2026Zilganersen approval brings new treatment approach for Alexander diseaseLauren Tochen, MD, of Children's National Hospital, discusses how the first disease-modifying therapy for Alexander disease could change care and diagnosis.Read more
November 4th, 2026Cenobamate sNDAs seek PGTC and pediatric focal seizure indicationsCenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.Read more
November 3rd, 2026FDA approves Lupin's generic amifampridine for LEMSFDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.Read more
November 18th, 2026Eczema linked to higher odds of sleep disturbance in childrenEczema was linked to 28% higher odds of sleep disturbance in a 26,395-patient pediatric primary care cohort presented at ACAAI 2026.Read more
November 18th, 2026Parenteral nutrition in preterm infants: Balancing benefits and risksDaniel Robinson, MD, discusses evidence-based parenteral nutrition practices, amino acid dosing, and opportunities to improve NICU protocols.Read more
November 17th, 2026FDA approves adrabetadex for infantile-onset Niemann-Pick type CThe FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.Read more
November 17th, 2026US loses measles elimination status; CDC outlines re-elimination planThe US lost measles elimination status after 26 years; CDC and partners plan to regain it via MMR vaccination and $100M in health department funding.Read more
November 17th, 2026Insurers denied 39% of pediatric allergy, asthma biologic requestsAt ACAAI 2026, 93.6% of pediatric biologic prescriptions needed prior authorization, 39.3% were denied, and approval took a mean of 33 days.Read more